Michael Gelband’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-47,605
| Closed | -$720K | – | 2312 |
|
|
2022
Q3 | $720K | Buy |
+47,605
| New | +$553K | 0.01% | 1239 |
|
|
2022
Q2 | – | Sell |
-75,097
| Closed | -$683K | – | 2717 |
|
|
2022
Q1 | $683K | Sell |
75,097
-12,958
| -15% | -$99.9K | 0.01% | 1359 |
|
|
2021
Q4 | $618K | Buy |
88,055
+68,388
| +348% | +$716K | 0.01% | 1287 |
|
|
2021
Q3 | $224K | Sell |
19,667
-19,419
| -50% | -$284K | ﹤0.01% | 1743 |
|
|
2021
Q2 | $626K | Buy |
39,086
+7,527
| +24% | +$129K | 0.01% | 1242 |
|
|
2021
Q1 | $564K | Buy |
+31,559
| New | +$545K | 0.01% | 1259 |
|
|
2020
Q3 | – | Sell |
-27,013
| Closed | -$399K | – | 2373 |
|
|
2020
Q2 | $399K | Buy |
+27,013
| New | +$400K | 0.01% | 1185 |
|
|
2019
Q4 | – | Sell |
-19,642
| Closed | -$378K | – | 1996 |
|
|
2019
Q3 | $378K | Buy |
19,642
+2,221
| +13% | +$50.9K | 0.01% | 784 |
|
|
2019
Q2 | $515K | Buy |
+17,421
| New | +$671K | 0.02% | 459 |
|
Michael Gelband's AERI Position: Q4 2022 in Review
Michael Gelband sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 47,605 shares — an estimated $720K sold.
Michael Gelband first reported a position in AERI in Q2 2019 and held it in 9 quarters. The position peaked at $720K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Michael Gelband reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Michael Gelband sold 47,605 Aerie Pharmaceuticals shares in Q4 2022, an estimated $720K.
- Michael Gelband first reported a position in Aerie Pharmaceuticals in Q2 2019 and held it in 9 quarters.
- Michael Gelband's Aerie Pharmaceuticals position peaked at $720K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.